Literature DB >> 15978113

A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance.

L Bodin, M H Horellou, C Flaujac, M A Loriot, M M Samama.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15978113     DOI： 10.1111/j.1538-7836.2005.01449.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  10 in total

Review 1.  Pharmacogenetics in Jewish populations.

Authors:  Yao Yang; Inga Peter; Stuart A Scott
Journal:  Drug Metabol Drug Interact       Date:  2014

2.  VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement.

Authors:  Helene Puehringer; Ralph M Loreth; Gudrun Klose; Brigitte Schreyer; Walter Krugluger; Barbara Schneider; Christian Oberkanins
Journal:  Eur J Clin Pharmacol       Date:  2010-04-08       Impact factor: 2.953

3.  Consequences of the Y139F Vkorc1 mutation on resistance to AVKs: in-vivo investigation in a 7th generation of congenic Y139F strain of rats.

Authors:  Agnes Grandemange; Michael Hans Kohn; Romain Lasseur; Christiane Longin-Sauvageon; Philippe Berny; Etienne Benoit
Journal:  Pharmacogenet Genomics       Date:  2009-10       Impact factor: 2.089

4.  Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing.

Authors:  Dana C Crawford; Marylyn D Ritchie; Mark J Rieder
Journal:  Pharmacogenomics       Date:  2007-05       Impact factor: 2.533

5.  Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms.

Authors:  Michael R Langley; Jessica K Booker; James P Evans; Howard L McLeod; Karen E Weck
Journal:  J Mol Diagn       Date:  2009-03-26       Impact factor: 5.568

6.  Evaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieu.

Authors:  Xuejie Chen; Da-Yun Jin; Darrel W Stafford; Jian-Ke Tie
Journal:  Blood       Date:  2018-08-08       Impact factor: 22.113

Review 7.  Warfarin pharmacogenetics.

Authors:  Nita A Limdi; David L Veenstra
Journal:  Pharmacotherapy       Date:  2008-09       Impact factor: 4.705

8.  A vitamin K epoxide reductase complex subunit 1 mutation in an Irish patient with warfarin resistance.

Authors:  F N Ainle; A Mumford; E Tallon; D McCarthy; K Murphy
Journal:  Ir J Med Sci       Date:  2008-02-12       Impact factor: 1.568

9.  Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.

Authors:  Stuart A Scott; Lisa Edelmann; Ruth Kornreich; Robert J Desnick
Journal:  Am J Hum Genet       Date:  2008-01-17       Impact factor: 11.025

10.  Adaptative evolution of the Vkorc1 gene in Mus musculus domesticus is influenced by the selective pressure of anticoagulant rodenticides.

Authors:  Joffrey Goulois; Véronique Lambert; Lionel Legros; Etienne Benoit; Virginie Lattard
Journal:  Ecol Evol       Date:  2017-03-21       Impact factor: 2.912
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.